Exosomes are one subtype within the broader extracellular vesicle category, distinguished by an intracellular formation pathway rather than budding directly from the outer cell membrane. In practice, confirming that a given preparation actually followed that pathway requires specific characterization work, such as imaging, marker analysis or biogenesis studies, which is why consensus guidelines caution against labeling every small EV preparation an exosome by default.
Commercial exosome products marketed to clinics are often derived from a source cell line and characterized using methods such as particle counting, marker detection and imaging; confirm the specific source and methods with the supplier for the product under review. Those characterization results describe what is present in a preparation, such as particle counts, surface markers and associated proteins, and are not evidence of any clinical effect. FDA has stated that no exosome product currently holds FDA approval, and that these products are generally regulated as biologic drugs under section 351 of the PHS Act, rather than under the framework that applies to some other human tissue products.
Because of that regulatory posture, a clinic considering an exosome product should treat the purchase and any clinical-use decision as a matter for its own regulatory counsel, request the supplier's underlying characterization and sourcing documentation, and treat marketing claims about what the product does for a condition as a compliance concern rather than a selling point. These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Exosome products carry a different, generally stricter regulatory classification than Wharton's jelly allografts, which changes what documentation and claims a clinic should expect from a supplier.